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Over the past 20 years, patients have increasingly been prescribed long-term courses of opioids for relief of their chronic musculoskeletal or cancer pain \[[@CR1]\]. While the central nervous system effects of these drugs have clearly helped ease the painful discomfort and improve quality of life for those afflicted, off-target side effects on the gastrointestinal tract are noted in as many as 40--50% of these patients \[[@CR2]--[@CR7]\]. These side effects are predominantly a very noticeable and unrelenting chronic constipation, the so-called opioid-induced constipation (OIC), which occurs within the first weeks of opioid treatment. To date, OIC is largely addressed by lifestyle modification in terms of increasing dietary fiber, rotating courses of therapy with alternative opioids or by taking concomitant laxatives or stool softeners \[[@CR8]\]. Despite these approaches, nearly 50% of OIC patients do not improve and for many, their symptoms are bothersome enough to lead to lowering or even skipping their opioid doses to improve their debilitating constipation \[[@CR9]\].

A variety of studies have sought to characterize the patient experience of both the nature of OIC-related discomfort and its impact on activities of daily living and ensuing quality of life. The symptoms of OIC frequently cited include having fewer than three bowel movements per week, bloating, cramping, infrequent passage of hard stools, straining, spasms, flatulence, hard and dry stools, nausea, vomiting, abdominal pain and reflux \[[@CR2], [@CR4], [@CR8], [@CR10]--[@CR12]\]. The impact of these symptoms has been shown to lead to impairment in the activities of daily living and work productivity \[[@CR13], [@CR14]\].

While it is clear that the hallmark of OIC is to experience infrequent bowel movements, it is not clear from prior patient research \[[@CR10], [@CR11]\] which of all the myriad OIC symptoms previously studied are the most important ones that patients would prefer to improve upon. Additionally, there is a lack of prior research to determine the effect size or degree of improvement patients are seeking in terms of increasing the number of bowel movements they experience per week due to OIC. The purpose of the present study was therefore to survey OIC patients to identify which of their many symptoms were viewed as those most important to be improved upon. We also sought to establish whether an increase of one more bowel movement per week was deemed sufficient to make a difference to patients suffering from OIC.

Methods {#Sec2}
=======

The study was designed as a cross-sectional, geographically dispersed online self-reported survey of patients experiencing OIC. Questions were designed with responses to be both categorical, using various scales, and also incorporate open-ended text to fully elucidate the nuances of the impact of OIC on patients' lives. The results from the free-text or qualitative responses are the subject of a separate paper.

Study participants were drawn from a large online patient database of over 800,000 individuals, and sampled within the following six countries: US, UK, Canada, Germany, Sweden and Norway. Participants were screened via e-mail and if they met the inclusion criteria, they were invited to participate in an online survey. The inclusion criteria were defined by each respondent meeting all of the following: minimum 18 years of age; self-reporting of chronic non-cancer pain; noting at least two active symptoms of OIC; taking a chronic course of opioid medications; confirming an ability to read or speak the language of the country the survey was administered; and a willingness and ability to provide written consent for participation.

The target sample size for the convenience sample was 500 respondents indicating they had OIC. Surveys were collected in May 2014 via a secured, online web-based survey system (HealthiVibe, LLC, Arlington, VA, USA). To do so, eligible participants were directed to a secure URL to access the survey that comprised a series of multiple-choice, closed-ended and free-text questions, which took approximately 12--15 min to complete.

The primary objectives of interest were to determine those symptoms of OIC that most patients (\>80%) would prefer to improve, and to determine whether one more bowel movement per week was considered 'extremely' or 'very' important to them, as phrased in the question: "How important is it to you to have one more bowel movement per week?" Pre-planned additional analyses were envisioned to determine which various potential patient subgroups were more or less likely to endorse this degree of symptomatic improvement.

Specific opioid drugs used by respondents were later dichotomized into a categorical variable with pharmacologically weak vs. strong opioids as follows: weak (tramadol, hydrocodone, codeine, dihydrocodeine) or strong (morphine, oxycodone, fentanyl, hydromorphone, methadone).

Statistical Analysis {#Sec3}
--------------------

Chi-square tests were used to assess bivariate associations for categorical variables. *t* tests assuming non-equal variance were used to evaluate differences for bivariate continuous variables. Logistic regression models were used to assess factors associated with participants agreeing that one more bowel movement per week was sufficient to be 'extremely' or 'very' important to them (vs. those stating it was only 'somewhat' or 'not' important). The regression model included participant age, gender, reporting of strong vs. weak opioid usage, severity of chronic pain on a scale of 0--10 (with increasing pain represented by increasing score), presence or absence of neuropathic pain, having fewer or more than three spontaneous bowel movements per week, and place of residence being a European or North American locale. Odds ratios were estimated to measure strengths of association and 95% confidence limits were estimated to assess precision. A *P* value \<0.05 was used to determine statistical significance. All analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
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Results {#Sec5}
=======

As noted in Table [1](#Tab1){ref-type="table"}, a total of 513 participants engaged in providing their input in the online survey. They were, on average, 46 years of age, with 55% female, 88.5% Caucasian, and most having at least high school education. There were approximately 100 (20%) participants from each of the following countries: US, Canada, Germany and the UK. The combined participation rate from the Nordic countries comprised 72 participants or 14.1% of the total sample. Very few participants (11%) self-reported being in either 'excellent' or 'very good' health (Table [2](#Tab2){ref-type="table"}). Participants could list multiple reasons for their chronic pain, with more than two-thirds indicating they had either back or musculoskeletal pain. Their average degree of pain on a 0--10 scale was 6.7, and they reported having their pain for a mean of 10.6 years. A little more than half reported taking pharmacologically strong opioids, while slightly fewer than half reported taking weaker opioids.Table 1Baseline characteristics of participantsCharacteristicParticipants (*n* = 513)Mean (SD) age, years46.1 (13.0)Female, *n* (%)282 (55)Country of residency, *n* (%) US112 (21.8) Canada113 (22.0) UK117 (22.8) Germany99 (19.3) Sweden50 (9.7) Norway22 (4.3)Caucasian, *n* (%)454 (88.5)\<High school graduate (or equivalent), *n* (%)40 (7.8)*SD* Standard deviationTable 2Clinical characteristics of participantsCharacteristicsParticipants (*n* = 513)Self-rating of health, *n* (%) Excellent13 (2.5) Very good46 (8.9) Good185 (36.1) Fair185 (36.1) Poor84 (16.4)Reason for pain, *n* (%) Back pain409 (79.7) Fibromyalgia104 (20.3) Headache254 (49.5) Joint pain358 (69.8) Nerve damage144 (28.1) Osteoarthritis145 (28.3) Pain syndrome106 (20.7) Rheumatoid arthritis119 (23.2)Mean (SD) rating of pain (in the past week) on a 0--10 scale6.7 (1.6)Mean (SD) duration of pain, years10.6 (9.5)Participants taking opioids by type, *n* (%) Strong opioids298 (58.1) Weak opioids215 (41.9)*SD* Standard deviation

The improvements that more than 80% of participants with OIC would prefer to see are to have bowel movements without pain, soft stools that are not loose or watery, a reduction in rectal straining, and relief from feeling bloated (see Table [3](#Tab3){ref-type="table"}). Additionally, more than 80% of participants with OIC would prefer to feel less fear about having OIC when they followed their opioid medication regime, worry less overall about having a bowel movement, and have less 'stomach' area pain. 79.3% of participants also stated they would prefer to avoid taking laxatives or suppositories to help with their constipation.Table 3Aspects of constipation most (≥80%) participants would prefer to improveAspectParticipants in agreement, %Be able to have a bowel movement without pain87.9Be able to have a soft stool that is not loose or watery87.1Not experience rectal straining due to my constipation83.4Feel less bloated83.0Be more comfortable using my opioid medication without fear of being constipated82.1Worry less about being able to have a bowel movement80.5Have less pain in my stomach area80.3

Being able to have a bowel movement on a 'regular' basis was considered an important symptom to improve upon by more than 86% of the respondents. When asked, "How important is it for you to have one more bowel movement per week?" over 90% responded that it was 'somewhat', 'very', or 'extremely' important, with over 70% (*n* = 354) supporting the 'extremely' or 'very' important response options (Table [4](#Tab4){ref-type="table"}). Respondents from the Nordic countries appeared to vary slightly in their response to this question compared with respondents from other countries in that 48% (Norway) and 57% (Sweden) considered one more bowel movement per week as being 'very' or 'extremely' important, compared with 70--83% of respondents from the other countries surveyed. Overall, only 3.9% of respondents felt that having one more bowel movement would not be an important difference representing an improvement in their condition. The remaining 4.3% of respondents indicated that they did not know whether one more bowel movement per week would make a difference to them and were not included in the table.Table 4Participants who considered that ≥1 more bowel movement per week was an important changeCountryParticipants (%) who considered the changeAt least 'somewhat' important^a^'Very' or 'extremely' importantCanada9983Germany9670Norway9048Sweden8757US9772UK9774Overall9672^a^Respondents endorsed this change as 'somewhat', 'very' or 'extremely' important

Nearly, 60% of respondents noted that they took less of their pain medication when they were constipated: 10% stated they 'always' took less pain medication while constipated, while an additional 19% stated they 'usually' took less pain medication; 30% stated they 'sometimes' took less.

Table [5](#Tab5){ref-type="table"} shows a comparison of some of the categorical factors evaluated for their association with the participants' response that having one more bowel movement per week was important. Numerically, more than 70% of younger adults (\<65 years) felt that having one more bowel movement per week was 'extremely' or 'very' important compared with 56% of those aged ≥65 years, though these differences were not statistically significant (it should be noted, however, that the sample size of those ≥65 years was small). As might be expected, more participants who had either fewer than three bowel movements per week or were in more severe pain endorsed the importance of having one more bowel movement per week.Table 5Bivariate analyses of selected patient factors in relation to the belief that one more bowel movement per week would make an important difference in OIC symptomsFactorResponse (%) to the question, "How important is it to you to have one more bowel movement per week?"ExtremelyVerySomewhatNot*P* valueAge, years \<65 (*n* = 468)37.233.1%21.63.9 ≥65 (*n* = 45)26.728.935.64.40.2841Weekly number of bowel movements \<3 (*n* = 225)40.935.618.71.3 ≥3 (*n* = 288)32.630.626.05.90.0086Mean pain score in the past week on a scale of 0--10 ≤7 (*n* = 369)32.533.126.04.3 \>7 (*n* = 144)45.831.914.62.80.0186Percentages may not sum to 100% as some participants indicated 'don't know' and are not depicted here. A response of 'don't know' did not exceed \>5%

Figure [1](#Fig1){ref-type="fig"} displays the box-and-whisker plot of results from the logistic regression equation to examine which of the factors were independently related to endorsing the importance of experiencing a single additional bowel movement per week. Again, being in more overall pain or reporting fewer than three bowel movements per week were found to be independent predictors, while age, gender, pharmacological strength of opioid taken, and geography of residence were not found to be predictors.Fig. 1Factors independently related to the response that having one more bowel movement per week was 'extremely' or 'very' important vs. all other responders. *PAIN_SCALE* refers to the numeric 0--10 response to the pain severity question; *SBM_LT3* refers to whether the patient had fewer than 3 spontaneous bowel movements per week

Discussion {#Sec6}
==========

Many studies have sought to understand the range of symptoms experienced by people living with OIC, though none have been designed to understand patients' specific preferences for which aspects are most important to improve. In our study, we found that more than 80% of 513 participants across six countries endorsed seeking an improvement in eight particular areas of concern that ranged from having regular bowel movements to assuaging fear and worry related to their condition. For individuals involved with the clinical monitoring of patients with OIC to detect an improvement in constipation, a specific focus on these symptoms seems warranted.

It is interesting that most patients in our study viewed having one more bowel movement per week as 'extremely' or 'very' important. This is a very telling finding in that even a seemingly small change was not deemed small to these patients. Clearly, the impact of OIC is important to these patients and a change is desired. While the study did not have sufficient statistical power to find a difference, numerically, those participants who were younger than 65 years of age appeared to be even more sensitive to this level of improvement. It is not surprising, as others have noted that OIC can adversely affect both workplace productivity and activities of daily living \[[@CR10]\], and those under the age of 65 are particularly vulnerable to either issue.

Our study noted a high proportion (60%) of patients who responded that they reduced their pain medication as a result of their constipation. Prior research with interviewer-administrated questionnaires, as opposed to our anonymized online survey, may result in social desirability response bias \[[@CR15]\], where the respondent seeks to please the interviewer and not provide responses that are counter to the interviewer's desire. Patient responses admitting to a self-initiated reduction in prescribed medication is not easy for patients. Therefore, our use of an anonymized online survey may have allowed a more honest response to this question leading to a seemingly high response confirming that patients reduced their pain medication.

It was noticeable that participants in our study who had chronic pain and were taking opioids experienced OIC scores much lower on the frequently utilized epidemiologic question asking patients to self-rate their overall general health. In a recent evaluation of the US National Health and Nutritious Examination Survey (NHANES) data, 17% of a representative sample of US residents reported their health as 'excellent' and 32% reported it as 'very good' \[[@CR16]\]. In our study, only 2.5% of respondents reported their health as 'excellent' with 8.9% reporting being in 'very good' health. Interestingly, a recently published study of similarly defined OIC participants found that only 1.4% of participants reported their health as 'excellent' and 6.7% as 'very good'; very close to our findings \[[@CR10]\]. We were not able to study the contribution of constipation to the diminished self-rated responses to general health perception, but it would be useful for future researchers to consider determining the degree to which the underlying physical reason for pain, the use of opioids, and/or the side effects of OIC contribute to these overall low ratings.

A potential limitation of our study was the way in which we drew our study sample from an online patient database. This could bias in favor of reflecting the preferences of a higher socioeconomic background than the average person with OIC. By definition, our participants had to be internet-savvy, and able and willing to participate in a web-based study. The fact that \>90% of our participants had completed at least high school education reflects their potentially high socioeconomic status. Yet, the demographic, clinical characteristics and overall health of our participants were very similar to those noted in a recently published study whose participants were drawn from primary care clinics, pain management clinics and clinical research sites across some of the same countries we studied (US, Canada, Germany, UK) \[[@CR10]\]. So while it may be that our participants were better educated, it does appear that they are otherwise similar to those OIC patients identified by other means.

Another limitation of our study was the lack of daily dosages of pain medications. However, we were able to obtain the name of the specific opioid and later stratified them into strong or weak opioids. The addition of daily dosage could have refined our analyses further.

Our study enrolled a relatively small sample size of older respondents. Our analysis of age in relation to the impact of OIC suggests that the problems and desired solutions were more pronounced among younger (\<65 years) than older (≥65 years) respondents. Future research should seek to enroll a wider age range to tease out the influence of age on desired health state.

Conclusions {#Sec7}
===========

Our study is the first to identify which of many OIC symptoms are most important to detect clinically meaningful improvement from a patient perspective. Additionally, we found that over 90% of patients reported that one more bowel movement per week was considered an important improvement in this overall problem, which is associated with chronic opioid usage. This degree of improvement may serve as an effect size or minimal clinically important difference for future research studies that seek to improve the condition of patients suffering from OIC.
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